Susanne Wilke is an active bio-entrepreneur, investor and a former VC, CEO and Board Member of Neurotrope Bioscience, Inc. (NTRP; NSDAQ). She joined the Board of Neurotrope in February 2016 and led Neurotrope as CEO from September 2016 – December 2017, during which she restructured Neurotrope, instituting a transformative strategy and business plan that encompassed financial, clinical, operational and commercial change. She was a consultant to the company prior to being a CEO and board member from 2015 – 2016. Prior to that, she worked as Managing Director of CrossBridge International, helping early-stage, high-growth biomedical companies to identify, prioritize and execute on strategic partnering and fundraising opportunities. Her earlier positions included Healthcare Strategy Consultant at the Monitor Company and Director of Worldwide Commercial Assessments at Forest Laboratories. Dr. Wilke also spent over 5 years in Venture Capital with Schroder Ventures Life Sciences and NGN Capital. Dr. Wilke holds a bachelor’s degree in biochemistry from Loyola University in Chicago, a dual Ph.D. in chemistry, biochemistry from University of Illinois at Chicago, and an MBA from Dartmouth College. Dr. Wilke also served as a Kauffman Fellow.